Evaluating a new radiotracer for cancer imaging
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
This study is testing a new imaging agent for cancer that helps doctors see tumors better by focusing on a specific protein found in cancer cells.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06438250 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety, biodistribution, and radiation dosimetry of a novel radiotracer called 68Ga-JH04, which targets fibroblast activation protein (FAP) in patients with various types of cancer. The research focuses on understanding how well this radiotracer accumulates in tumors compared to normal tissues, leveraging the overexpression of FAP in malignant neoplasms. By assessing the dosimetric characteristics of 68Ga-JH04, the study aims to provide insights into its potential utility for cancer diagnosis and treatment monitoring.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with various solid tumors who have confirmed histopathological findings.
Not a fit: Patients who are pregnant, lactating, or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of cancer imaging and improve treatment planning for patients with malignant tumors.
How similar studies have performed: Previous studies with other FAP-targeting tracers have shown promising results, indicating a potential for success with this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Various solid tumors with available histopathological findings * Signed informed consent Exclusion Criteria: * pregnant or lactational women * who suffered from severe hepatic and renal insufficiency
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Principal investigator: Weibing Miao, MD — The First Affiliated Hospital, Fujian Medical University
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: +86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.